Full abstract details including title and text are currently available to registrants via the AACR online itinerary planner. A copy of the presentation will be available in the Posters and ...

VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS ...

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

SOUTH SAN FRANCISCO, CA, USA I April 01, 2025 I TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage ...

IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline ...

US oncology biotech Inspirna is winding down after a decade of operations, according to a LinkedIn post from chief executive Usman Azam. He said the New York-based company would close after “ten ...

The disease is caused by mutations in one gene — cystic fibrosis transmembrane conductance regulator, or CFTR — making it, in theory, an ideal candidate for gene-editing technology. However, there’s a ...

The genetic makeup of his tumor showed a specific gene mutation. "The gene can have a ... "These are the so-called RAS inhibitors." Research indicates that RAS inhibitors target a specific protein ...

BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing ...

Servier will be responsible for the development and commercialization of BDTX-4933, a Phase I asset targeting solid tumors with RAS and RAF mutations. Black Diamond’s stock jumped more than 40% in pre ...

Comprehensive maps of mutations in healthy and diseased gastric tissue give clues about how cancer arises and could inform early-detection strategies. Read the paper: The somatic mutation ...